INT-004 Chronic hepatitis C: information brochure for patients under new direct acting antivirals

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Clinical research for the treatment of chronic hepatitis C has evolved greatly with the introduction on the European pharmaceutical market of new oral direct acting antivirals (DAAs). Despite the fact that new DAA agents have fewer side effects, it is important to provide appropriate information to patients at initiation of treatment.

Purpose

To develop and implement a therapeutic education tool for patients with chronic hepatitis C, and to provide accurate information during the pharmaceutical consultations organised at the hospital.

Material and methods

The following steps were followed.

Material and methods

Design viral hepatitis C brochure after review of:

Material and methods

Write new information sections for DAAs for the following drugs: siméprévir–sofosbuvir–ombitasvir+dasabuvir+paritaprevir/ritonavir–ledipasvir+sofosbuvir. Validate the therapeutic education tool by hospital pharmacists and gastroenterologists involved in the treatment of chronic hepatitis C.

Results

The edition of the final patient information brochure (format A6) contained several sections, such as:

Conclusion

Implementation of this information brochure allowed the hospital pharmacist to provide well summarised information on hepatitis C virus treatment. It is a useful tool during pharmaceutical consultations with chronic hepatitis C patients. The personalised information booklet provided to the patients can also be shared at home with the family, allowing them to have more details on hepatitis C disease and on the patient’s drug regimen.

References and/or acknowledgements

EASL (European Association for the Study of Liver): recommendations on treatment of hepatitis C2015.

References and/or acknowledgements

AASLD (American Association for the Study of Liver Diseases): recommendations on treatment of hepatitis C 2015.

References and/or acknowledgements

Summary of DAAs characteristics 2015.

References and/or acknowledgements

No conflict of interest

Related Topics

    loading  Loading Related Articles